Matrix metalloproteinases: Fold and function of their catalytic domains

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1803, Issue 1, 2010, Pages 20-28

  Tallant, Cynthia ^a   Marrero, Aniebrys ^a   Gomis Rüth, F Xavier ^a  

^a INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

Author keywords

Catalytic domain; Metallopeptidase; Metzincin; MMP; Three dimensional structure; Vertebrate collagenase; X ray crystal structure; Zinc metalloproteinase

Indexed keywords

BATIMASTAT; CIPEMASTAT; ENZYME PRECURSOR; ILOMOSTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; UNCLASSIFIED DRUG; ZINC;

AMINO ACID SEQUENCE; BINDING SITE; CATALYSIS; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME KINETICS; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; CATALYTIC DOMAIN; ENZYME PRECURSORS; HUMANS; MATRIX METALLOPROTEINASES; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; ZINC;

VERTEBRATA;

EID: 77149154385     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2009.04.003     Document Type: Review

References (92)

1. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92:827-839.
2. Murphy G., Nagase H. Progress in matrix metalloproteinase research. Mol. Aspects Med. 2008, 29:290-308.
3. Gomis-Rüth F.X. Structural aspects of the metzincin clan of metalloendopeptidases. Mol. Biotech. 2003, 24:157-202.
4. Gomis-Rüth F.X. Catalytic domain architecture of metzincin metalloproteases. J. Biol. Chem. 2009, 284(23):15353-15357.
5. Bode W., Gomis-Rüth F.X., Stöcker W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the metzincins. FEBS Lett. 1993, 331:134-140.
6. Stöcker W., Grams F., Baumann U., Reinemer P., Gomis-Rüth F.X., McKay D.B., Bode W. The metzincins topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Prot. Sci. 1995, 4:823-840.
7. Gross J., Lapière C.M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. U. S. A. 1962, 48:1014-1022.
8. Gross J. How tadpoles lose their tails: path to discovery of the first matrix metalloproteinase. Matrix Biol. 2004, 23:3-13.
9. Lapière C.M. Tadpole collagenase, the single parent of such a large family. Biochimie 2005, 87:243-247.
10. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev., Cancer 2002, 2:161-174.
11. Brinckerhoff C.E., Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev., Mol. Cell Biol. 2002, 3:207-214.
12. Edwards D.R., Handsley M.M., Pennington C.J., The ADAM metalloproteinases. Mol. Aspects Med. 2008, 29:258-289.
13. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev., Cancer 2008, 8:929-941.
14. Overall C.M., Blobel C.P. In search of partners: linking extracellular proteases to substrates. Nat. Rev., Mol. Cell Biol. 2007, 8:245-257.
15. Overall C.M., López-Otín C. Strategies for MMP inhibition in cancer; innovations for the post-trial era. Nat. Rev., Cancer 2002, 2:657-672.
16. Puente X.S., Sánchez L.M., Overall C.M., López-Otín C. Human and mouse proteases: a comparative genomic approach. Nat. Rev., Genet. 2003, 4:544-558.
17. Quesada V., Ordoñez G.R., Sánchez L.M., Puente X.S., López-Otn C. The Degradome database: mammalian proteases and diseases of proteolysis. Nucl. Acids Res. 2009, 37(Database issue):D239-D243.
18. Uría J.A., López-Otín C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res. 2000, 60:4745-4751.
19. Blundell T.L. Metalloproteinase superfamilies and drug design. Nat. Struct. Biol. 1994, 1:73-75.
20. Woessner J.F., Nagase H. Matrix Metalloproteinases and TIMPs (Protein Profile Series- Ed. P. Sheterline) 2000, Oxford Univ. Press, New York.
21. Overall C.M. Matrix metalloproteinase substrate binding domains, modules and exosites. Overview and experimental strategies. Meth. Mol. Biol. 2001, 151:79-120.
22. Birkedal-Hansen H., Moore W.G., Bodden M.K., Windsor L.J., Birkedal-Hansen B., DeCarlo A., Engler J.A. Matrix metalloproteinases: a review. Crit. Rev. Oral. Biol. Med. 1993, 4:197-205.
23. Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274:21491-21494.
24. Gomis-Rüth F.X. Hemopexin domains. Handbook of Metalloproteins. 2004, vol. 3:631-646. John Wiley and Sons, Ltd., Chichester (UK. A. Messerschmidt, W. Bode, M. Cygler (Eds.).
25. Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 2005, 87:249-263.
26. Nagase H., Fushimi K. Elucidating the function of non catalytic domains of collagenases and aggrecanases. Connect. Tissue Res. 2008, 49:169-174.
27. Nagase H. Substrate specificity of MMPs. Matrix Metalloproteinase Inhibitors in Cancer Therapy. 2000, 39. Humana Press, Totowa, NJ. N.J. Clendeninn, K. Appelt (Eds.).
28. Murphy G., Stanton H., Cowell S., Butler G., Knäuper V., Atkinson S., Gavrilovic J. Mechanisms for pro-matrix metalloproteinase activation. APMIS 1999, 107:38-44.
29. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol. Chem. 1997, 378:151-160.
30. Springman E.B., Angleton E.L., Birkedal-Hansen H., Van Wart H.E. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:364-368.
31. Van Wart H.E., Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:5578-5582.
32. Stetler-Stevenson W.G., Seo D.W. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol. Med. 2005, 11:97-103.
33. Duncan W.C., Illingworth P.J., Fraser H.M. Expression of tissue inhibitor of metalloproteinases-1 in the primate ovary during induced luteal regression. J. Endocrinol. 1996, 151:203-213.
34. Kikuchi K., Kadono T., Furue M., Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J. Invest. Dermatol. 1997, 108:281-284.
35. Hayakawa T., Yamashita K., Tanzawa K., Uchijima E., Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992, 298:29-32.
36. Rao B.G. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des. 2005, 11:295-322.
37. Schechter I., Berger A. On the size of active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27:157-162.
38. Gomis-Rüth F.X., Stöcker W., Huber R., Zwilling R., Bode W. Refined 1.8Å X-ray crystal structure of astacin, a zinc-endopeptidase from the crayfish Astacus astacus L. Structure determination, refinement, molecular structure and comparison with thermolysin. J. Mol. Biol. 1993, 229:945-968.
39. Reinemer P., Grams F., Huber R., Kleine T., Schnierer S., Piper M., Tschesche H., Bode W. Structural implications for the role of the N terminus in the superactivation of collagenases. A crystallographic study. FEBS Lett. 1994, 338:227-233.
40. Grams F., Crimmin M., Hinnes L., Huxley P., Pieper M., Tschesche H., Bode W. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry 1995, 34:14012-14020.
41. Maskos K., Bode W. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Mol. Biotechnol. 2003, 25:241-266.
42. Hege T., Baumann U. The conserved methionine residue of the metzincins: a site-directed mutagenesis study. J. Mol. Biol. 2001, 314:181-186.
43. Pieper M., Betz M., Budiša N., Gomis-Rüth F.X., Bode W., Tschesche H. Expression, purification, characterization, and X-ray analysis of selenomethionine 215 variant of leukocyte collagenase. J. Protein Chem. 1997, 16:637-650.
44. Butler G.S., Tam E.M., Overall C.M. The canonical methionine 392 of matrix metalloproteinase 2 (gelatinase A) is not required for catalytic efficiency or structural integrity: probing the role of the methionine-turn in the metzincin metalloprotease superfamily. J. Biol. Chem. 2004, 279:15615-15620.
45. Oberholzer A.E., Bumann M., Hege T., Russo S., Baumann U. The metzincin's canonical methionine is responsible for the structural integrity of the zinc-binding site. Biol. Chem. 2009, 390(9):875-881.
46. Auld D.S. Catalytic mechanisms for metallopeptidases. Handbook of Proteolytic Enzymes. 2004, vol. 1:268-289. Elsevier Academic Press, London. A.J. Barrett, N.D. Rawlings, J.F. Woessner (Eds.).
47. Gomis-Rüth F.X. Structure and mechanism of metallocarboxypeptidases. Crit. Rev. Biochem. Mol. Biol. 2008, 43:319-345.
48. Matthews B.W. Structural basis of the action of thermolysin and related zinc peptidases. Acc. Chem. Res. 1988, 21:333-340.
49. Pelmenschikov V., Siegbahn P.E.M. Catalytic mechanism of matrix metalloproteinases: two-layered ONIOM study. Inorg. Chem. 2002, 41:5659-5666.
50. Johnson L.L., Pavlovsky A.G., Johnson A.R., Janowicz J.A., Man C.F., Ortwine D.F., Purchase C.F., 2nd A.D., White D.J., Hupe A rationalization of the acidic pH dependence for stromelysin-1 (Matrix metalloproteinase-3) catalysis and inhibition. J. Biol. Chem. 2000, 275:11026-11033.
51. Bertini I., Calderone V., Fragai M., Luchinat C., Maletta M., Yeo K.J. Snapshots of the reaction mechanism of matrix metalloproteinases. Angew. Chem. Int. Ed. Engl. 2006, 45:7952-7955.
52. Lovejoy B., Hassell A.M., Luther M.A., Weigl D., Jordan S.R. Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. Biochemistry 1994, 33:8207-8217.
53. Solomon A., Akabayov B., Frenkel A., Milla M.E., Sagi I. Key feature of the catalytic cycle of TNF-α converting enzyme involves communication between distal protein sites and the enzyme catalytic core. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4931-4936.
54. 2O of zinc enzymes. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:220-224.
55. March J. Advanced Organic Chemistry Reactions, Mechanisms and Structure 1985, John Wiley and Sons, Inc., New York. 3rd ed.
56. Monzingo A.F., Matthews B.W. Binding of N-carboxymethyl dipeptide inhibitors to thermolysin determined by X-ray crystallography: a novel class of transition-state analogues for zinc peptidases. Biochemistry 1984, 23:5724-5729.
57. Hangauer D.G., Monzingo A.F., Matthews B.W. An interactive computer graphics study of thermolysin-catalyzed peptide cleavage and inhibition by N-carboxymethyl dipeptides. Biochemistry 1984, 23:5730-5741.
58. Morgunova E., Tuuttila A., Bergmann U., Isupov M., Lindqvist Y., Schneider G., Tryggvason K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999, 284:1667-1670.
59. Morgunova E., Tuuttila A., Bergmann U., Tryggvason K. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7414-7419.
60. Becker J.W., Rokosz M.A.I.L.L., Axel M.G., Burbaum J.J., Fitzgerald P.M., Cameron P.M., Esser C.K., Hagmann W.K., Hermes J.D., Springer J.P. Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Prot. Sci. 1995, 4:1966-1976.
61. Jozic D., Bourenkov G., Lim N.H., Visse R., Nagase H., Bode W., Maskos K. X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding. J. Biol. Chem. 2005, 280:9578-9585.
62. Elkins P.A., Ho Y.S., Smith W.W., Janson C.A., D'Alessio K.J., McQueney M.S., Cummings M.D., Romanic A.M. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Cryst. 2002, D58:1182-1192.
63. Wetmore D.R., Hardman K.D. Roles of the propeptide and metal ions in the folding and stability of the catalytic domain of stromelysin (matrix metalloproteinase 3). Biochemistry 1996, 35:6549-6558.
64. Vallee B.L., Auld D.S. Zinc coordination, function, and structure of zinc enzymes and other proteins. Biochemistry 1990, 29:5647-5659.
65. Bode W., Maskos K. Structural studies on MMPs and TIMPs. Meth. Mol. Biol. 2001, 151:145-177.
66. Cha J., Pedersen M.V., Auld D.S. Metal and pH dependence of heptapeptide catalysis by human matrilysin. Biochemistry 1996, 35:15831-15838.
67. Loechel F., Overgaard M.T., Oxvig C., Albrechtsen R., Wewer U.M. Regulation of human ADAM 12 protease by the prodomain. Evidence for a functional cysteine switch. J. Biol. Chem. 1999, 274:13427-13433.
68. Grams F., Huber R., Kress L.F., Moroder L., Bode W. Activation of snake venom metalloproteinases by a cysteine switch-like mechanism. FEBS Lett. 1993, 335:76-80.
69. Milla M.E., Gonzáles P.E., Leonard J.D. The TACE zymogen: re-examining the role of the cysteine switch. Cell Biochem. Biophys. 2006, 44:342-348.
70. Tallant C., García-Castellanos R., Seco J., Baumann U., Gomis-Rüth F.X. Molecular analysis of ulilysin, the structural prototype of a new family of metzincin metalloproteases. J. Biol. Chem. 2006, 281:17920-17928.
71. Osenkowski P., Toth M., Fridman R. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J. Cell. Physiol. 2004, 200:2-10.
72. Overall C.M., Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 2006, 94:941-946.
73. Dive V., Georgiadis D., Matziari M., Makaritis A., Beau F., Cuniasse P., Yiotakis A. Phosphinic peptides as zinc metalloproteinase inhibitors. Cell Mol. Life Sci. 2004, 61:2010-2019.
74. Engel C.K., Pirard B., Schimanski S., Kirsch R., Habermann J., Klingler O., Schlotte V., Weithmann K.U., Wendt K.U. Structural basis for the highly selective inhibition of MMP-13. Chem. Biol. 2005, 12:181-189.
75. 1' subsite of matrix metalloproteinase 8 (MMP-8). J. Med. Chem. 2009, 52(4):1040-1049.
76. Yiotakis A., Dive V. Synthetic active site-directed inhibitors of metzincins: achievement and perspectives. Mol. Aspects Med. 2008, 29:329-338.
77. Rosenblum G., Meroueh S.O., Kleifeld O., Brown S., Singson S.P., Fridman R., Mobashery S., Sagi I. Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2). J. Biol. Chem. 2003, 278:27009-27015.
78. Dublanchet A.C., Ducrot P., Andrianjara C., O'Gara M., Morales R., Compere D., Denis A., Blais S., Cluzeau P., Courte K., Hamon J., Moreau F., Prunet M.L., Tertre A. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:3787-3790.
79. Devel L., Rogakos V., David A., Makaritis A., Beau F., Cuniasse P., Yiotakis A., Dive V. Development of selective inhibitors and substrate of matrix metalloproteinase-12. J. Biol. Chem. 2006, 281:11152-11160.
80. Yun M., Park C., Kim S., Nam D., Kim S.C., Kim D.H. The x-ray crystallographic study of covalently modified carboxypeptidase A by 2-benzyl-3,4-epoxybutanoic acid, a pseudomechanism-based inactivator. J. Am. Chem. Soc. 1992, 114:2281-2282.
81. Kim D.H. Chemistry-based design of inhibitors for carboxypeptidase A. Curr. Top. Med. Chem. 2004, 4:1217-1226.
82. Brown P.D., Davidson A.H., Drummond A.H., Gearing A., Whittaker M. Hydroxamic acid matrix metalloproteinase inhibitors. Matrix Metalloproteinase Inhibitors in Cancer Therapy. 2001, 113-142. Humana Press, New Jersey. N.J. Clendeninn, K. Appelt (Eds.).
83. Ikejiri M., Bernardo M.M., Meroueh S.O., Brown S., Chang M., Fridman R., Mobashery S. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J. Org. Chem. 2005, 70:5709-5712.
84. Hodgson J.A. Remodeling MMPIs. Biotechnology 1995, 30:554-557.
85. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
86. Konstantinopoulos P.A., Karamouzis M.V., Papatsoris A.G., Papavassiliou A.G. Matrix metalloproteinase inhibitors as anticancer agents. Int. J. Biochem. Cell Biol. 2008, 40:1156-1168.
87. López-Otín C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 2007, 7:800-808.
88. Puerta D.T., Lewis J.A., Cohen S.M. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. J. Am. Chem. Soc. 2004, 126:8388-8389.
89. Evans S.V. SETOR: hardware lighted three-dimensional solid model representations of macromolecules. J. Mol. Graphics 1993, 11:134-138.
90. Mosca R., Schneider T.R. RAPIDO: a web server for the alignment of protein structures in the presence of conformational changes. Nucleic Acids Res. 2008, 36:W42-W466.
91. C. Carranza, A.-G. Inisan, E. Mouthuy-Knoops, C. Cambillau, A. Roussel, Turbo-Frodo., AFMB Activity Report 1996-1999, CNRS-UPR 9039, Marseille, 1999, pp. 89-90.
92. Betz M., Huxley P., Davies S.J., Mushtaq Y., Pieper M., Tschesche H., Bode W., Gomis-Rüth F.X. 1.8-Å crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur. J. Biochem. 1997, 247:356-363.